Skip to main content
Erschienen in: Pediatric Drugs 1/2006

01.01.2006 | Review Article

ACE Inhibitors in Pediatric Patients with Heart Failure

verfasst von: Dr Kazuo Momma

Erschienen in: Pediatric Drugs | Ausgabe 1/2006

Einloggen, um Zugang zu erhalten

Abstract

This article reviews reports of ACE inhibitor use in pediatric heart failure and summarizes the present implications for clinical practice. Captopril, enalapril, and cilazapril are orally active ACE inhibitors, and widely used in pediatric cardiology, although more than ten other ACE inhibitors have been applied clinically in adults. Effects of ACE inhibitors on the renin-angiotensin-aldosterone system in pediatric patients are similar to those in adults. ACE inhibitors lower aortic pressure and systemic vascular resistance, do not affect pulmonary vascular resistance significantly, and lower left atrial and right atrial pressures in pediatric patients with heart failure. In infants with a large ventricular septal defect and pulmonary hypertension, ACE inhibitors decrease left-to-right shunt in those infants with elevated systemic vascular resistance. ACE inhibitors induce a small increase in left ventricular ejection fraction, left ventricular fractional shortening, and systemic blood flow in children with left ventricular dysfunction, mitral regurgitation, and aortic regurgitation. These beneficial effects usually persist long term without the development of tolerance. Therapeutic trials of ACE inhibitors have been reported in children with heart failure and divergent hemodynamics, including myocardial dysfunction, left-to-right shunt, such as large ventricular septal defect and pulmonary hypertension, aortic or mitral regurgitation, and Fontan circulation.
Hypotension and renal failure usually occur within 5 days after starting ACE inhibition or increasing the dose and, in most cases, recovery is seen after reduction or cessation of the drug. With all ACE inhibitors, smaller doses are administered initially to prevent excessive hypotension, and doses are increased gradually to the target dose. Captopril is administered orally, usually every 8 hours. Daily doses range from 0.3 to 1.5 mg/kg in children. Enalapril is administered orally, once or twice a day, and daily doses range from 0.1 to 0.5 mg/kg. Enalaprilat is administered intravenously, one to three times a day, in doses ranging from 0.01 to 0.05 mg/kg/dose.
For the treatment of chronic heart failure in children, ACE inhibitors are essential along with other medications including diuretics, digoxin, and β-blockers (β-adrenoceptor antagonists).
Literatur
1.
Zurück zum Zitat Nadas AS, Fyler DC. Pediatric cardiology. 3rd ed. Philadelphia (PA): Saunders, 1972: 262–75 Nadas AS, Fyler DC. Pediatric cardiology. 3rd ed. Philadelphia (PA): Saunders, 1972: 262–75
2.
Zurück zum Zitat Keith JD, Rowe RD, Vlad P. Heart disease in infancy and childhood. 3rd ed. New York: Macmillan, 1978: 163–84 Keith JD, Rowe RD, Vlad P. Heart disease in infancy and childhood. 3rd ed. New York: Macmillan, 1978: 163–84
3.
Zurück zum Zitat Taylor JFN. The management of heart failure in paediatric practice. In: Graham G, Rossi E, editors. Heart disease in infants and children. London: Edward Arnold, 1980: 151–66 Taylor JFN. The management of heart failure in paediatric practice. In: Graham G, Rossi E, editors. Heart disease in infants and children. London: Edward Arnold, 1980: 151–66
4.
Zurück zum Zitat Talner NS. Heart failure. In: Moss AJ, Adams FH, Emmanouilides GC, editors. Heart disease in infants, children, and adolescents. 2nd ed. Baltimore (MD): Williams & Wilkins, 1977: 660–75 Talner NS. Heart failure. In: Moss AJ, Adams FH, Emmanouilides GC, editors. Heart disease in infants, children, and adolescents. 2nd ed. Baltimore (MD): Williams & Wilkins, 1977: 660–75
5.
Zurück zum Zitat Gorodischer R. Cardiac drugs. In: Yaffe SI, editor. Pediatric pharmacology. New York: Grune & Stratton, 1980: 281–304 Gorodischer R. Cardiac drugs. In: Yaffe SI, editor. Pediatric pharmacology. New York: Grune & Stratton, 1980: 281–304
6.
Zurück zum Zitat Talner NS. Heart failure. In: Adams FH, Emmanouilides GC, editors. Moss’ heart disease in infants, children, and adolescents. 3rd ed. Baltimore (MD): Williams & Wilkins, 1983: 708–24 Talner NS. Heart failure. In: Adams FH, Emmanouilides GC, editors. Moss’ heart disease in infants, children, and adolescents. 3rd ed. Baltimore (MD): Williams & Wilkins, 1983: 708–24
7.
Zurück zum Zitat Cohn JN, Franciosa JA. Vasodilator therapy of cardiac failure (first of two parts). N Engl J Med 1977; 297(1): 27–31PubMedCrossRef Cohn JN, Franciosa JA. Vasodilator therapy of cardiac failure (first of two parts). N Engl J Med 1977; 297(1): 27–31PubMedCrossRef
8.
Zurück zum Zitat Cohn JN, Franciosa JA. Vasodilator therapy of cardiac failure (second of two parts). N Engl J Med 1977; 297(5): 254–8PubMedCrossRef Cohn JN, Franciosa JA. Vasodilator therapy of cardiac failure (second of two parts). N Engl J Med 1977; 297(5): 254–8PubMedCrossRef
9.
Zurück zum Zitat Rubin SA, Swan HJC. Vasodilator therapy for heart failure: concept, applications, and challenges. JAMA 1981 Feb; 245: 761–3PubMedCrossRef Rubin SA, Swan HJC. Vasodilator therapy for heart failure: concept, applications, and challenges. JAMA 1981 Feb; 245: 761–3PubMedCrossRef
10.
Zurück zum Zitat Katz AM. Changing strategies in the management of heart failure. J Am Coll Cardiol 1989; 13(3): 513–23PubMedCrossRef Katz AM. Changing strategies in the management of heart failure. J Am Coll Cardiol 1989; 13(3): 513–23PubMedCrossRef
11.
Zurück zum Zitat Mason DT. Afterload reduction and cardiac performance: physiologic basis of systemic vasodilators as a new approach in treatment of congestive heart failure. Am J Med 1978; 65: 106–25PubMedCrossRef Mason DT. Afterload reduction and cardiac performance: physiologic basis of systemic vasodilators as a new approach in treatment of congestive heart failure. Am J Med 1978; 65: 106–25PubMedCrossRef
12.
Zurück zum Zitat Chatterjee K, Parmley WW, Cohn JN, et al. A cooperative multicenter study of captopril in congestive heart failure: hemodynamic effects and long-term response. Am Heart J 1985; 110: 439–47PubMedCrossRef Chatterjee K, Parmley WW, Cohn JN, et al. A cooperative multicenter study of captopril in congestive heart failure: hemodynamic effects and long-term response. Am Heart J 1985; 110: 439–47PubMedCrossRef
13.
Zurück zum Zitat Artman M. Pharmacological therapy. In: Emmanouilides GC, Riemenschneider TA, Allen HD, et al., editors. Moss and Adams’ heart disease in infants, children, and adolescents. 5th ed. Baltimore (MD): Williams & Wilkins, 1995: 375–98 Artman M. Pharmacological therapy. In: Emmanouilides GC, Riemenschneider TA, Allen HD, et al., editors. Moss and Adams’ heart disease in infants, children, and adolescents. 5th ed. Baltimore (MD): Williams & Wilkins, 1995: 375–98
14.
Zurück zum Zitat Dillon TR, Janos GG, Meyer RA, et al. Vasodilator therapy for congestive heart failure. J Pediatr 1980 Apr; 96(4): 623–9PubMedCrossRef Dillon TR, Janos GG, Meyer RA, et al. Vasodilator therapy for congestive heart failure. J Pediatr 1980 Apr; 96(4): 623–9PubMedCrossRef
15.
Zurück zum Zitat Talner NS. Heart failure. In: Adams FH, Emmanouilides GC, editors. Moss’ heart disease in infants, children, and adolescents. 4th ed. Baltimore (MD): Williams & Wilkins, 1989: 890–910 Talner NS. Heart failure. In: Adams FH, Emmanouilides GC, editors. Moss’ heart disease in infants, children, and adolescents. 4th ed. Baltimore (MD): Williams & Wilkins, 1989: 890–910
16.
Zurück zum Zitat Beekman RH, Rocchini AP, Rosenthal A. Hemodynamic effects of nitroprusside in infants with a large ventricular septal defect. Circulation 1981; 64(3): 553–8PubMedCrossRef Beekman RH, Rocchini AP, Rosenthal A. Hemodynamic effects of nitroprusside in infants with a large ventricular septal defect. Circulation 1981; 64(3): 553–8PubMedCrossRef
17.
Zurück zum Zitat Dzau VJ, Colucci WS, Hollenberg NK, et al. Relation of renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63: 645–51PubMedCrossRef Dzau VJ, Colucci WS, Hollenberg NK, et al. Relation of renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63: 645–51PubMedCrossRef
18.
Zurück zum Zitat Curtiss C, Cohn JN, Vrobel T, et al. Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation 1978; 58: 763–70PubMedCrossRef Curtiss C, Cohn JN, Vrobel T, et al. Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation 1978; 58: 763–70PubMedCrossRef
19.
Zurück zum Zitat Jackson EK, Garrison JC. Renin and angiotensin. In: Hardman JG, Limbird LE, Morlinjoff PB, et al. editors. Goodman & Gilman’s pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 733–58 Jackson EK, Garrison JC. Renin and angiotensin. In: Hardman JG, Limbird LE, Morlinjoff PB, et al. editors. Goodman & Gilman’s pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 733–58
20.
Zurück zum Zitat Davis R, Ribner HS, Keung E, et al. Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin-converting enzyme. N Engl J Med 1979; 301: 117–21PubMedCrossRef Davis R, Ribner HS, Keung E, et al. Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin-converting enzyme. N Engl J Med 1979; 301: 117–21PubMedCrossRef
21.
Zurück zum Zitat Schneeweiss A. Drug therapy in infants and children with cardiovascular disease. Philadelphia (PA): Lee & Febiger, 1986: 181–232 Schneeweiss A. Drug therapy in infants and children with cardiovascular disease. Philadelphia (PA): Lee & Febiger, 1986: 181–232
22.
Zurück zum Zitat Friedman WF, George BL. Treatment of congestive heart failure by altering loading conditions of the heart. J Pediatr 1985; 106(5): 697–706PubMedCrossRef Friedman WF, George BL. Treatment of congestive heart failure by altering loading conditions of the heart. J Pediatr 1985; 106(5): 697–706PubMedCrossRef
23.
Zurück zum Zitat Gottlieb SS, Dickstein K, Fleck E, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993; 88 (Pt 1): 1602–9PubMedCrossRef Gottlieb SS, Dickstein K, Fleck E, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993; 88 (Pt 1): 1602–9PubMedCrossRef
24.
Zurück zum Zitat Pitt B, Poole-Wilson AP, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial. The Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–7PubMedCrossRef Pitt B, Poole-Wilson AP, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial. The Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–7PubMedCrossRef
25.
Zurück zum Zitat Williams Jr JF, Bristow MR, Fowler MB, et al. Guidelines for evaluation and management of heart failure: report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 1995; 26: 1376–98CrossRef Williams Jr JF, Bristow MR, Fowler MB, et al. Guidelines for evaluation and management of heart failure: report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 1995; 26: 1376–98CrossRef
26.
Zurück zum Zitat Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task force on practice guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure). Circulation 2001; 104: 2996–3007PubMedCrossRef Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task force on practice guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure). Circulation 2001; 104: 2996–3007PubMedCrossRef
27.
Zurück zum Zitat Waagstein F, Hjalmarson A, Varnauskas E, et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 1022–36PubMedCrossRef Waagstein F, Hjalmarson A, Varnauskas E, et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 1022–36PubMedCrossRef
28.
Zurück zum Zitat Cohn JN, Levine TB, Olivari MT, et al. Plasma noradrenaline as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819–23PubMedCrossRef Cohn JN, Levine TB, Olivari MT, et al. Plasma noradrenaline as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819–23PubMedCrossRef
29.
Zurück zum Zitat Engelmeier RS, O’Connell JB, Walsh R, et al. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985; 72(3): 536–46PubMedCrossRef Engelmeier RS, O’Connell JB, Walsh R, et al. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985; 72(3): 536–46PubMedCrossRef
30.
Zurück zum Zitat Eichhorn EJ, Bristow MR. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol 1997; 79: 794–7PubMedCrossRef Eichhorn EJ, Bristow MR. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol 1997; 79: 794–7PubMedCrossRef
31.
Zurück zum Zitat Olson TM, Chan DP. Dilated congestive cardiomyopathy. In: Allen HD, Gutgesell HP, Clark EB, et al., editors. Moss and Adams’ heart disease in infants, children, and adolescents. 6th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2001: 1187–96 Olson TM, Chan DP. Dilated congestive cardiomyopathy. In: Allen HD, Gutgesell HP, Clark EB, et al., editors. Moss and Adams’ heart disease in infants, children, and adolescents. 6th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2001: 1187–96
32.
Zurück zum Zitat Colucci WS, Braunwald E. Pathophysiology of heart failure. In: Braunwald E. Zipes DP, Libby P, editors. Heart disease. 6th ed. Philadelphia (PA): W.B. Saunders, 2001: 503–33 Colucci WS, Braunwald E. Pathophysiology of heart failure. In: Braunwald E. Zipes DP, Libby P, editors. Heart disease. 6th ed. Philadelphia (PA): W.B. Saunders, 2001: 503–33
33.
Zurück zum Zitat Talner NS, McGovern JJ, Carboni MP. Congestive heart failure. In: Moller JH, Hoffman JIE, editors. Pediatric cardiovascular medicine. New York: Churchill Livingstone, 2000: 817–32 Talner NS, McGovern JJ, Carboni MP. Congestive heart failure. In: Moller JH, Hoffman JIE, editors. Pediatric cardiovascular medicine. New York: Churchill Livingstone, 2000: 817–32
34.
Zurück zum Zitat Tynan M, Anderson RH. Ventricular septal defect. In: Anderson RH, Baker EJ, Macartney RFJ, et al., editors. Paediatric cardiology. 2nd ed. London: Churchill Livingstone, 2002: 983–1014 Tynan M, Anderson RH. Ventricular septal defect. In: Anderson RH, Baker EJ, Macartney RFJ, et al., editors. Paediatric cardiology. 2nd ed. London: Churchill Livingstone, 2002: 983–1014
35.
Zurück zum Zitat Calvalho JS. Cardiomyopathies. In: Anderson RH, Baker EJ, Macartney RFJ, et al., editors. Paediatric cardiology. 2nd ed. London: Churchill Livingstone, 2002: 1595–643 Calvalho JS. Cardiomyopathies. In: Anderson RH, Baker EJ, Macartney RFJ, et al., editors. Paediatric cardiology. 2nd ed. London: Churchill Livingstone, 2002: 1595–643
36.
Zurück zum Zitat Baylen BG, Johnson G, Tsang R, et al. The occurrence of hyperaldosteronism in infants with congestive heart failure. Am J Cardiol 1980; 45: 305–10PubMedCrossRef Baylen BG, Johnson G, Tsang R, et al. The occurrence of hyperaldosteronism in infants with congestive heart failure. Am J Cardiol 1980; 45: 305–10PubMedCrossRef
37.
Zurück zum Zitat Hein S, Arnon E, Kostin S, et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart. Circulation 2003; 107: 984–91PubMedCrossRef Hein S, Arnon E, Kostin S, et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart. Circulation 2003; 107: 984–91PubMedCrossRef
38.
Zurück zum Zitat Baker KM, Aceto JE. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cell. Am J Physiol 1990; 259: H610–8PubMed Baker KM, Aceto JE. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cell. Am J Physiol 1990; 259: H610–8PubMed
39.
Zurück zum Zitat Sadoshima J, Izumo S. Signal transduction pathways of angiotensin II-induced c-fos gene expression in cardiac myocytes in vitro. Circ Res 1993; 73: 424–38PubMedCrossRef Sadoshima J, Izumo S. Signal transduction pathways of angiotensin II-induced c-fos gene expression in cardiac myocytes in vitro. Circ Res 1993; 73: 424–38PubMedCrossRef
40.
Zurück zum Zitat Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Circ Res 1993; 73: 413–23PubMedCrossRef Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Circ Res 1993; 73: 413–23PubMedCrossRef
41.
Zurück zum Zitat Suzuki J, Matsubara H, Urakami M, et al. Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res 1993; 73: 439–47PubMedCrossRef Suzuki J, Matsubara H, Urakami M, et al. Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res 1993; 73: 439–47PubMedCrossRef
42.
Zurück zum Zitat Pinto YM, Pinto-Siesma S-J, Philipp T, et al. Reduction in left ventricular messenger RNA for transforming growth factor betal attenuates left ventricular fibrosis and improves survival without lowering blood pressure in hypertensive TGR(mRen2)27 rat. Hypertension 2000; 36: 747–54PubMedCrossRef Pinto YM, Pinto-Siesma S-J, Philipp T, et al. Reduction in left ventricular messenger RNA for transforming growth factor betal attenuates left ventricular fibrosis and improves survival without lowering blood pressure in hypertensive TGR(mRen2)27 rat. Hypertension 2000; 36: 747–54PubMedCrossRef
43.
Zurück zum Zitat Schultz JEJ, Witt SA, Glascock BJ, et al. TGF-betal mediate the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 2002; 109: 787–96 Schultz JEJ, Witt SA, Glascock BJ, et al. TGF-betal mediate the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 2002; 109: 787–96
44.
Zurück zum Zitat Kromer EP, Riegger GAJ. Effects of long-term angiotensin converting enzyme inhibition on myocardial hypertrophy in experimental aortic stenosis in the rat. Am J Cardiol 1988; 62: 161–3PubMedCrossRef Kromer EP, Riegger GAJ. Effects of long-term angiotensin converting enzyme inhibition on myocardial hypertrophy in experimental aortic stenosis in the rat. Am J Cardiol 1988; 62: 161–3PubMedCrossRef
45.
Zurück zum Zitat Osaki S, Kinugawa T, Ogino K, et al. Effects of acute and chronic alacepril treatment on exercise capacity and hemodynamics in patients with heart failure: a preliminary study. Int J Clin Pharmacol Therap 2002; 40(2): 69–74 Osaki S, Kinugawa T, Ogino K, et al. Effects of acute and chronic alacepril treatment on exercise capacity and hemodynamics in patients with heart failure: a preliminary study. Int J Clin Pharmacol Therap 2002; 40(2): 69–74
46.
Zurück zum Zitat Grassi G, Cattaneo BM, Seravalle G, et al. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation 1997; 96: 1173–9PubMedCrossRef Grassi G, Cattaneo BM, Seravalle G, et al. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation 1997; 96: 1173–9PubMedCrossRef
47.
Zurück zum Zitat Cremonesi G, Cavalieri L, Cikes I, et al. Fixed combinations of delapril plus indapamide vs fosinopril plus hydrochlorothiazide in mild to moderate essential hypertension. Adv Ther 2002; 19(3): 129–37PubMedCrossRef Cremonesi G, Cavalieri L, Cikes I, et al. Fixed combinations of delapril plus indapamide vs fosinopril plus hydrochlorothiazide in mild to moderate essential hypertension. Adv Ther 2002; 19(3): 129–37PubMedCrossRef
48.
Zurück zum Zitat Auslender M, Artman M. Drugs and dosages. In: Moller JH, Hoffman JIE, editors. Pediatric cardiovascular medicine. New York: Churchill Livingstone, 2000: 953–69 Auslender M, Artman M. Drugs and dosages. In: Moller JH, Hoffman JIE, editors. Pediatric cardiovascular medicine. New York: Churchill Livingstone, 2000: 953–69
49.
Zurück zum Zitat Pinto YM, van Veldhuisen DJ, Tjon-Ka-Jie RT, et al. Dose-finding study of imidapril, a novel angiotensin converting enzyme inhibitor, in patients with stable chronic heart failure. Europ J Clin Pharmacol 1996; 50(4): 265–8CrossRef Pinto YM, van Veldhuisen DJ, Tjon-Ka-Jie RT, et al. Dose-finding study of imidapril, a novel angiotensin converting enzyme inhibitor, in patients with stable chronic heart failure. Europ J Clin Pharmacol 1996; 50(4): 265–8CrossRef
50.
Zurück zum Zitat Simpson K, Jarvis B. Lisinopril: a review of its use in congestive heart failure. Drugs 2000; 59(5): 1149–67PubMedCrossRef Simpson K, Jarvis B. Lisinopril: a review of its use in congestive heart failure. Drugs 2000; 59(5): 1149–67PubMedCrossRef
51.
Zurück zum Zitat Simpson D, Noble S, Goa KL. Perindopril: in congestive heart failure. Drugs 2002; 629: 1367–77CrossRef Simpson D, Noble S, Goa KL. Perindopril: in congestive heart failure. Drugs 2002; 629: 1367–77CrossRef
52.
Zurück zum Zitat Acanfora D, Furgi G, Trojano L, et al. Quinapril in patients with congestive heart failure: controlled trial versus captopril. Am J Therapeut 1997; 4: 181–8CrossRef Acanfora D, Furgi G, Trojano L, et al. Quinapril in patients with congestive heart failure: controlled trial versus captopril. Am J Therapeut 1997; 4: 181–8CrossRef
53.
Zurück zum Zitat Lamy A, Yusuf S, Pogue J, et al. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcome Prevention Evaluation (HOPE) study. Circulation 2003; 107: 960–5PubMedCrossRef Lamy A, Yusuf S, Pogue J, et al. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcome Prevention Evaluation (HOPE) study. Circulation 2003; 107: 960–5PubMedCrossRef
54.
Zurück zum Zitat Iwanaga Y, Kihara Y, Inagaki K, et al. Differential effects of angiotensin II versus endothelin-1 inhibitions in hypertrophie left ventricular myocardium during transition to heart failure. Circulation 2001; 104(4): 606–12PubMedCrossRef Iwanaga Y, Kihara Y, Inagaki K, et al. Differential effects of angiotensin II versus endothelin-1 inhibitions in hypertrophie left ventricular myocardium during transition to heart failure. Circulation 2001; 104(4): 606–12PubMedCrossRef
55.
Zurück zum Zitat Mulder P, Boujedaini H, Richard V, et al. Long-term survival and hemodynamics after endothelin-a receptor antagonism and angiotensin-converting enzyme inhibition in rats with chronic heart failure: monotherapy versus combined therapy. Circulation 2002; 106(9): 1159–64PubMedCrossRef Mulder P, Boujedaini H, Richard V, et al. Long-term survival and hemodynamics after endothelin-a receptor antagonism and angiotensin-converting enzyme inhibition in rats with chronic heart failure: monotherapy versus combined therapy. Circulation 2002; 106(9): 1159–64PubMedCrossRef
56.
Zurück zum Zitat Beekman RH, Rocchini AP, Dick II M, et al. Vasodilator therapy in children: acute and chronic effects in children with left ventricular dysfunction or mitral regurgitation. Pediatrics 1984; 37(1): 43–51 Beekman RH, Rocchini AP, Dick II M, et al. Vasodilator therapy in children: acute and chronic effects in children with left ventricular dysfunction or mitral regurgitation. Pediatrics 1984; 37(1): 43–51
57.
Zurück zum Zitat Shaw NJ, Wilson N, Dickinson DF. Captopril in heart failure secondary to a left to right shunt. Arch Dis Childh 1988; 63: 360–3PubMedCrossRef Shaw NJ, Wilson N, Dickinson DF. Captopril in heart failure secondary to a left to right shunt. Arch Dis Childh 1988; 63: 360–3PubMedCrossRef
58.
Zurück zum Zitat Shaddy RE, Teitel DF, Brett C. Short-term hemodynamic effects of captopril in infants with congestive heart failure. Am J Dis Child 1988; 142(1): 100–5PubMed Shaddy RE, Teitel DF, Brett C. Short-term hemodynamic effects of captopril in infants with congestive heart failure. Am J Dis Child 1988; 142(1): 100–5PubMed
59.
Zurück zum Zitat Scammell AM, Arnold R. The effect of the first dose of captopril on blood pressure in infants in heart failure. Int J Cardiol 1089; 22: 377–9CrossRef Scammell AM, Arnold R. The effect of the first dose of captopril on blood pressure in infants in heart failure. Int J Cardiol 1089; 22: 377–9CrossRef
60.
Zurück zum Zitat Montigny M, Davignon A, Fouron J-C, et al. Captopril in infants for congestive heart failure secondary to a large ventricular left-to-right shunt. Am J Cardiol 1989; 63(5): 631–3PubMedCrossRef Montigny M, Davignon A, Fouron J-C, et al. Captopril in infants for congestive heart failure secondary to a large ventricular left-to-right shunt. Am J Cardiol 1989; 63(5): 631–3PubMedCrossRef
61.
Zurück zum Zitat Schneeweiss A. Cardiovascular drugs in children II: angiotensin-converting enzyme inhibitors in pediatric patients. Pediatr Cardiol 1990; 11: 199–207PubMedCrossRef Schneeweiss A. Cardiovascular drugs in children II: angiotensin-converting enzyme inhibitors in pediatric patients. Pediatr Cardiol 1990; 11: 199–207PubMedCrossRef
62.
Zurück zum Zitat Stern H, Weil J, Genz T, et al. Captopril in children with dilated cardiomyopathy: acute and long-term effects in a prospective study of hemodynamic and hormonal effects. Pediatr Cardiol 1990; 11(1): 22–8PubMedCrossRef Stern H, Weil J, Genz T, et al. Captopril in children with dilated cardiomyopathy: acute and long-term effects in a prospective study of hemodynamic and hormonal effects. Pediatr Cardiol 1990; 11(1): 22–8PubMedCrossRef
63.
Zurück zum Zitat Bengur AR, Beekman RH, Rocchini AP, et al. Acute hemodynamic effects of captopril in children with a congestive or restrictive cardiomyopathy. Circulation 1991; 83(2): 523–7PubMedCrossRef Bengur AR, Beekman RH, Rocchini AP, et al. Acute hemodynamic effects of captopril in children with a congestive or restrictive cardiomyopathy. Circulation 1991; 83(2): 523–7PubMedCrossRef
64.
Zurück zum Zitat Lewis AB, Chabot M. The effects of treatment with angiotensin-converting enzyme inhibitors on survival of pediatric patients with dilated cardiomyopathy. Pediatr Cardiol 1993; 14(1): 9–12PubMed Lewis AB, Chabot M. The effects of treatment with angiotensin-converting enzyme inhibitors on survival of pediatric patients with dilated cardiomyopathy. Pediatr Cardiol 1993; 14(1): 9–12PubMed
65.
Zurück zum Zitat Alehan D, Ozkutlu S. Beneficial effects of 1-year captopril therapy in children with chronic aortic regurgitation who have no symptoms. Am Heart J 1988; 135(4): 598–603CrossRef Alehan D, Ozkutlu S. Beneficial effects of 1-year captopril therapy in children with chronic aortic regurgitation who have no symptoms. Am Heart J 1988; 135(4): 598–603CrossRef
66.
Zurück zum Zitat Frenneaux M, Stewart RAH, Newman CMH, et al. Enalapril for severe heart failure in infancy. Arch Dis Child 1989; 64: 219–23PubMedCrossRef Frenneaux M, Stewart RAH, Newman CMH, et al. Enalapril for severe heart failure in infancy. Arch Dis Child 1989; 64: 219–23PubMedCrossRef
67.
Zurück zum Zitat Lloyd TP, Mahoney L, Knoedel P, et al. Orally administered enalapril for infants with congestive heart failure: a dose-finding study. J Pediatr 1989; 114(4): 650–4PubMedCrossRef Lloyd TP, Mahoney L, Knoedel P, et al. Orally administered enalapril for infants with congestive heart failure: a dose-finding study. J Pediatr 1989; 114(4): 650–4PubMedCrossRef
68.
Zurück zum Zitat Rheuban KS, Carpenter MA, Ayers CA, et al. Acute hemodynamic effects of converting enzyme inhibition in infants with congestive heart failure. J Pediatr 1990; 117(4): 668–70PubMedCrossRef Rheuban KS, Carpenter MA, Ayers CA, et al. Acute hemodynamic effects of converting enzyme inhibition in infants with congestive heart failure. J Pediatr 1990; 117(4): 668–70PubMedCrossRef
69.
Zurück zum Zitat Seguchi M, Nakazawa M, Momma K. Effect of enalapril on infants and children with congestive heart failure. Cardiol Young 1992; 2(1): 14–9CrossRef Seguchi M, Nakazawa M, Momma K. Effect of enalapril on infants and children with congestive heart failure. Cardiol Young 1992; 2(1): 14–9CrossRef
70.
Zurück zum Zitat Webster MWI, Neutze JM, Calder AL. Acute hemodynamic effects of converting enzyme inhibition in children with intracardiac shunts. Pediatr Cardiol 1992; 13: 129–35PubMed Webster MWI, Neutze JM, Calder AL. Acute hemodynamic effects of converting enzyme inhibition in children with intracardiac shunts. Pediatr Cardiol 1992; 13: 129–35PubMed
71.
Zurück zum Zitat Sluysmans T, Styns-Cailteux M, Tremouroux-Wattiez M, et al. Intravenous enalaprilat and oral enalapril in congestive heart failure secondary to ventricular septal defect in infancy. Am J Cardiol 1992; 70(2): 959–62PubMedCrossRef Sluysmans T, Styns-Cailteux M, Tremouroux-Wattiez M, et al. Intravenous enalaprilat and oral enalapril in congestive heart failure secondary to ventricular septal defect in infancy. Am J Cardiol 1992; 70(2): 959–62PubMedCrossRef
72.
Zurück zum Zitat Leversha AM, Wilson NJ, Clarkson PM, et al. Efficacy and dosage of enalapril in congenital and acquired heart disease. Arch Dis Child 1994; 70(1): 35–9PubMedCrossRef Leversha AM, Wilson NJ, Clarkson PM, et al. Efficacy and dosage of enalapril in congenital and acquired heart disease. Arch Dis Child 1994; 70(1): 35–9PubMedCrossRef
73.
Zurück zum Zitat Eronen M, Pesonen E, Wallgren EI, et al. Enalapril in children with congestive heart failure. Acta Paediatr Scand 1991; 80: 555–8PubMedCrossRef Eronen M, Pesonen E, Wallgren EI, et al. Enalapril in children with congestive heart failure. Acta Paediatr Scand 1991; 80: 555–8PubMedCrossRef
74.
Zurück zum Zitat Nakamura H, Ishii M, Sugimura T, et al. The kinetic profile and enalaprilat and their possible developmental changes in pediatric patients with congestive heart failure. Clin Pharmacol Ther 1994; 56(2): 160–8PubMedCrossRef Nakamura H, Ishii M, Sugimura T, et al. The kinetic profile and enalaprilat and their possible developmental changes in pediatric patients with congestive heart failure. Clin Pharmacol Ther 1994; 56(2): 160–8PubMedCrossRef
75.
Zurück zum Zitat Kouatli AA, Garcia JA, Zellers TM, et al. Enalapril does not enhance exercise capacity in patients after Fontan procedure. Circulation 1997; 96: 1507–12PubMedCrossRef Kouatli AA, Garcia JA, Zellers TM, et al. Enalapril does not enhance exercise capacity in patients after Fontan procedure. Circulation 1997; 96: 1507–12PubMedCrossRef
76.
Zurück zum Zitat Ohuchi H, Hasegawa S, Yasuda K, et al. Severely impaired cardiac autonomic nervous action after the Fontan operation. Circulation 2001; 104: 1513–8PubMedCrossRef Ohuchi H, Hasegawa S, Yasuda K, et al. Severely impaired cardiac autonomic nervous action after the Fontan operation. Circulation 2001; 104: 1513–8PubMedCrossRef
77.
Zurück zum Zitat Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002; 20(23): 4517–22PubMedCrossRef Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002; 20(23): 4517–22PubMedCrossRef
78.
Zurück zum Zitat Kura S, Tunaoglu FS, Olgunturk R, et al. Atrial natriuretic peptide levels in rheumatic mitral regurgitation and response to angiotensin-converting enzyme inhibitors. Canad J Cardiol 2003; 19(4): 405–8 Kura S, Tunaoglu FS, Olgunturk R, et al. Atrial natriuretic peptide levels in rheumatic mitral regurgitation and response to angiotensin-converting enzyme inhibitors. Canad J Cardiol 2003; 19(4): 405–8
79.
Zurück zum Zitat Mori Y, Nakazawa M, Tomimatsu H, et al. Long-term effect of angiotensin-converting enzyme inhibitor in volume overloaded heart failure during growth: a controlled pilot study. J Am Coll Cardiol 2000; 36(1): 270–5PubMedCrossRef Mori Y, Nakazawa M, Tomimatsu H, et al. Long-term effect of angiotensin-converting enzyme inhibitor in volume overloaded heart failure during growth: a controlled pilot study. J Am Coll Cardiol 2000; 36(1): 270–5PubMedCrossRef
80.
Zurück zum Zitat Hazama K, Nakazawa M, Momma K. Effective dose and cardiovascular effects of cilazapril in children with heart failure. Am J Cardiol 2001; 88(2): 801–5PubMedCrossRef Hazama K, Nakazawa M, Momma K. Effective dose and cardiovascular effects of cilazapril in children with heart failure. Am J Cardiol 2001; 88(2): 801–5PubMedCrossRef
81.
Zurück zum Zitat Gavras H, Faxon DP, Berkoben J, et al. Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation 1978; 58(5): 770–6PubMedCrossRef Gavras H, Faxon DP, Berkoben J, et al. Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation 1978; 58(5): 770–6PubMedCrossRef
82.
Zurück zum Zitat Fagard R, Bulpitt C, Lunen P, et al. Response of the systemic and pulmonary circulation to converting-enzyme inhibition (captopril) at rest and during exercise in hypertensive patients. Circulation 1982; 65(1): 33–9PubMedCrossRef Fagard R, Bulpitt C, Lunen P, et al. Response of the systemic and pulmonary circulation to converting-enzyme inhibition (captopril) at rest and during exercise in hypertensive patients. Circulation 1982; 65(1): 33–9PubMedCrossRef
83.
Zurück zum Zitat Cleland JGF, Dargie HJ, Hodsman GP, et al. Captopril in heart failure: a double blind controlled trial. Br Heart J 1984; 52: 530–5PubMedCrossRef Cleland JGF, Dargie HJ, Hodsman GP, et al. Captopril in heart failure: a double blind controlled trial. Br Heart J 1984; 52: 530–5PubMedCrossRef
84.
Zurück zum Zitat Levine TB, Olivari MT, Cohn JN. Hemodynamic and regional blood flow response to captopril in congestive heart failure. Am J Med 1984; 76: 38–42PubMedCrossRef Levine TB, Olivari MT, Cohn JN. Hemodynamic and regional blood flow response to captopril in congestive heart failure. Am J Med 1984; 76: 38–42PubMedCrossRef
85.
Zurück zum Zitat Kramer BL, Massie BM, Topic N. Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study. Circulation 1983; 67(4): 807–16PubMedCrossRef Kramer BL, Massie BM, Topic N. Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study. Circulation 1983; 67(4): 807–16PubMedCrossRef
86.
Zurück zum Zitat Packer M, Medina N, Yushak M, et al. Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure. Circulation 1983; 68(4): 803–12PubMedCrossRef Packer M, Medina N, Yushak M, et al. Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure. Circulation 1983; 68(4): 803–12PubMedCrossRef
87.
Zurück zum Zitat CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429–35CrossRef CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429–35CrossRef
88.
Zurück zum Zitat Creager MA, Massie BM, Faxon DP, et al. Acute and long-term effects of enalapril on cardiovascular response to exercise and exercise tolerance in patients with congestive heart failure. J Am Coll Cardiol 1985; 6(1): 163–70PubMedCrossRef Creager MA, Massie BM, Faxon DP, et al. Acute and long-term effects of enalapril on cardiovascular response to exercise and exercise tolerance in patients with congestive heart failure. J Am Coll Cardiol 1985; 6(1): 163–70PubMedCrossRef
89.
Zurück zum Zitat Swedberg K, Eneroth P, Kjekshus J, et al. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). Am J Cardiol 1990; 66: 40D–5DPubMedCrossRef Swedberg K, Eneroth P, Kjekshus J, et al. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). Am J Cardiol 1990; 66: 40D–5DPubMedCrossRef
90.
Zurück zum Zitat Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303–10PubMedCrossRef Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303–10PubMedCrossRef
91.
Zurück zum Zitat Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986; 314(24): 1547–52PubMedCrossRef Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986; 314(24): 1547–52PubMedCrossRef
92.
Zurück zum Zitat SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302CrossRef SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302CrossRef
93.
Zurück zum Zitat Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on mortality and morbidity in chronic heart failure. Circulation 1999; 100: 2312–8PubMedCrossRef Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on mortality and morbidity in chronic heart failure. Circulation 1999; 100: 2312–8PubMedCrossRef
94.
Zurück zum Zitat Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril: ten year follow-up of CONSENSUS I. Eur Heart J 1999; 20: 136–9PubMedCrossRef Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril: ten year follow-up of CONSENSUS I. Eur Heart J 1999; 20: 136–9PubMedCrossRef
95.
Zurück zum Zitat AIRE Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–8 AIRE Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–8
96.
Zurück zum Zitat Drakos SG, Papamichael CM, Alexopoulos GP, et al. Effects of high doses versus standard doses of enalapril on endothelial cell function in patients with chronic congestive heart failure secondary to idiopathic dilated or ischemic cardiomy-opathy. Am J Cardiol 2003; 91: 885–8PubMedCrossRef Drakos SG, Papamichael CM, Alexopoulos GP, et al. Effects of high doses versus standard doses of enalapril on endothelial cell function in patients with chronic congestive heart failure secondary to idiopathic dilated or ischemic cardiomy-opathy. Am J Cardiol 2003; 91: 885–8PubMedCrossRef
97.
Zurück zum Zitat HOPE Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253–9CrossRef HOPE Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253–9CrossRef
98.
Zurück zum Zitat Arnold JMO, Yusuf S, Young J, et al. Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2003; 107: 1284–90PubMedCrossRef Arnold JMO, Yusuf S, Young J, et al. Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2003; 107: 1284–90PubMedCrossRef
99.
Zurück zum Zitat Ooi H, Colucci WS. Pharmacological treatment of heart failure. In: Hardman JG, Limbird LE, editors. Goodman & Gilman’s pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001: 901–32 Ooi H, Colucci WS. Pharmacological treatment of heart failure. In: Hardman JG, Limbird LE, editors. Goodman & Gilman’s pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001: 901–32
100.
Zurück zum Zitat Todd PA, Heel RC. Enalapril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1986; 31: 198–248PubMedCrossRef Todd PA, Heel RC. Enalapril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1986; 31: 198–248PubMedCrossRef
101.
Zurück zum Zitat Stingo L, Pocock WA, Flax H, et al. Long-term captopril therapy in severe refractory congestive heart failure. Br J Clin Pharmac 1982; 14: 203S–8SCrossRef Stingo L, Pocock WA, Flax H, et al. Long-term captopril therapy in severe refractory congestive heart failure. Br J Clin Pharmac 1982; 14: 203S–8SCrossRef
102.
Zurück zum Zitat Sharpe N, Murphy J, Smith H, et al. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1988; 331: 255–9CrossRef Sharpe N, Murphy J, Smith H, et al. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1988; 331: 255–9CrossRef
103.
Zurück zum Zitat Artman M. Drugs and dosages. In: Allen HD, Gutgesell HP, Clark EB, et al., editors. Moss and Adams’ heart disease in infants, children, and adolescents. 6th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2001: 1459–68 Artman M. Drugs and dosages. In: Allen HD, Gutgesell HP, Clark EB, et al., editors. Moss and Adams’ heart disease in infants, children, and adolescents. 6th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2001: 1459–68
104.
Zurück zum Zitat Auslender M, Artman M. Drugs and dosages. In: Möller JH, Hoffman JIC, editors. Pediatric cardiovascular medicine. New York: Churchill Livingstone, 2000: 953–69 Auslender M, Artman M. Drugs and dosages. In: Möller JH, Hoffman JIC, editors. Pediatric cardiovascular medicine. New York: Churchill Livingstone, 2000: 953–69
105.
Zurück zum Zitat Perry JC. Drug formulary. In: Garson Jr A, Bricker JT, Fisher DJ, et al., editors. The science and practice of pediatric cardiology. 2nd ed. Baltimore (MD): Williams & Wilkins, 1998: 2950–6 Perry JC. Drug formulary. In: Garson Jr A, Bricker JT, Fisher DJ, et al., editors. The science and practice of pediatric cardiology. 2nd ed. Baltimore (MD): Williams & Wilkins, 1998: 2950–6
106.
Zurück zum Zitat Linseman JV, Bristow MR. Drug therapy and heart failure prevention. Circulation 2003; 107: 1234–6PubMedCrossRef Linseman JV, Bristow MR. Drug therapy and heart failure prevention. Circulation 2003; 107: 1234–6PubMedCrossRef
Metadaten
Titel
ACE Inhibitors in Pediatric Patients with Heart Failure
verfasst von
Dr Kazuo Momma
Publikationsdatum
01.01.2006
Verlag
Springer International Publishing
Erschienen in
Pediatric Drugs / Ausgabe 1/2006
Print ISSN: 1174-5878
Elektronische ISSN: 1179-2019
DOI
https://doi.org/10.2165/00148581-200608010-00005

Weitere Artikel der Ausgabe 1/2006

Pediatric Drugs 1/2006 Zur Ausgabe

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.